Once you’ve decided to deploy the FDA-approved amikacin liposome inhaled aerosol suspension in patients with refractory MAC lung disease, how do you use to optimize patient adherence, tolerability and compliance with this treatment?

Once you’ve decided to deploy the FDA-approved amikacin liposome inhaled aerosol suspension in patients with refractory MAC lung disease, how do you use to optimize patient adherence, tolerability and compliance with this treatment?

Once you’ve made the decision to deploy the FDA-approved amikacin liposome inhaled aerosol suspension in patients with refractory MAC lung disease, what strategies do you use to optimize patient adherence, tolerability and compliance with this treatment?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Shannon Kasperbauer, MD

Shannon Kasperbauer, MD

Associate Professor of Medicine Department of Medicine Division of Mycobacterial & Respiratory Infections National Jewish Denver, Colorado